Pharmaxis
(ASX:PXS) has announced it has completed recruitment of an international clinical trial evaluating its Bronchitol drug.
Subject to a positive trial outcome, the company will seek approval from the US FDA to distribute the drug in the US.
Bronchitol is used to treat patients suffering from Cystic Fibrosis and is currently approved for use in Australia, the EU and Israel.
Pharmaxis has partnered with global pharmaceutical provider Chiesi to fund the trials and to sell and distribute the product.
Pharmaxis reported a net loss of $11.18 million at 31 December 2015.
